Phase II Trial of High-Dose Cytosine Arabinoside and Cisplatin in Recurrent Squamous Carcinoma of the Head and Neck A Piedmont Oncology Association Study

Bl, Powell; Jb, Craig; Hb, Muss; Pj, Zekan; Mr, Cooper; Fm, Schnell; Jw, Hampton; Dr, White; Lr, Smith; Rl, Capizzi

doi:10.1097/00000421-198810000-00008

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Potentiation of cisplatin cytotoxic activity by short infusional high dose cytarabine, backed up by previous experimental data [16,17] and some phase II studies [18][19][20][21] also brought both statistically and clinically signifi cant benefi t either for response rate or overall survival both in neoadjuvant and palliative setting [22].…”

Section: Improving or Replacing The 5-fu-cisplatin Regimenmentioning

confidence: 88%

“…Th ree to four cycles of ICT with docetaxel plus cisplatin and fl ourouracil (TPF) showed to be superior to ICT with cisplatin and fl ourouracil alone (PF) followed by CRT or RT and led to impoved overall survival in two large trails [12,13]. Although the studies comparing ICT with TPF to CRT alone show promising intermediate results, concomitant platin-based chemoradiotherapy remains standard until further notice in the treatment of locoregionally advanced unresectable head and neck cancer [14,15].Potentiation of cisplatin cytotoxic activity by short infusional high dose cytarabine, backed up by previous experimental data [16,17] and some phase II studies [18][19][20][21] also brought both statistically and clinically signifi cant benefi t either for response rate or overall survival both in neoadjuvant and palliative setting [22]. …”

mentioning

confidence: 98%

See 1 more Smart Citation

Head and neck cancer: a step forward

Jelić¹,

Popov²,

Schartinger

et al. 2010

memo

View full text Add to dashboard Cite

Head and neck cancers have for a long time been orphan cancers for any trials of individualized treatment, at least in part because the number of active cytotoxic drugs has been for a long time rather restricted. Histology did not infl uence treatment modality and the use of particular cytotoxic drugs. Undiff erentiated carcinoma of the nasopharynx was the fi rst tumour type to enhance investigations in individualized treatment, as regards to choice of cytotoxic drugs and combinations of chemo and radiotherapy. Recently the HPV16/18 positive carcinoma of the oropharynx has arisen as a topic for individualized approach. Th e biologicals are relatively late newcomers in the arsenal of drugs available for head and neck cancer. Th e same statement is related to research of possible targets and thus investigations of subpopulations that might benefi t from a particular drug or a particular pathway inhibition. Individualized drug treatment in head and neck cancer appears to be at its promising beginnings. The past decadesIn the last two decades, until recently, few advances have been made in the treatment of head and neck cancer, either in adjuvant, neoadjuvant, concomitant and palliative setting.Since meta-analyses showed a benefi t, concurrent chemoradiotherapy (CRT) widely replaced radiotherapy (RT) alone in the treatment of unresectable head and neck sqamous cell carcinoma (HNSCC) [1][2][3]. Th e principal cytostatic drugs have shown to be 5-fl ourouracil alone, cisplatin alone, mitomycin C alone, or 5-FU and cisplatin [4]. Amongst the platinum derivatives, cisplatin has been proven to be the drug of choice, more active in single drug setting than its analogue carboplatin and therefore the combination of cisplatin and continuously infusional 5-FU emerged as the treatment of choice [5,6]. Th e continuous infusional 5-FU-cisplatin regimen remained the standard, occasional although phase II trials appeared to demonstrate that the 4 h infusional 5-FU was as active as continuous infusional 5-FU when combined to cisplatin in both neoadjuvant and palliative setting [7]. Other cytostatic drugs like capecitabine in combination with paclitaxel or cisplatin are found to be well tolerated and eff ective but still fail to convince as a fi rst-line treatment in unresectable HNSCC [8,9]. Bleomycin and methotrexat in combination with radiation even showed to considerably enhance acute mucosal toxicity without any survival benefi t and therefore have been exluded from a large meta-analysis [1]. In the last decades the unconventional fractionated therapy has been studied extensively and showed that hyperfractionation leads to signifi cant improvement of overall survival, if used as a single modality. On the other hand accelerated radiotherapy alone is not that eff ective, especially in extreme treatments with decreased doses or split course radiation shedule [1,10]. Th e role of altered fractionated radiotherapy in the combined setting with chemotherapy is less conclusive and still under investigation.In adjuvant treatment CRT shoul...

show abstract

Section: Improving or Replacing The 5-fu-cisplatin Regimenmentioning

confidence: 88%

mentioning

confidence: 98%

Head and neck cancer: a step forward

Jelić¹,

Popov²,

Schartinger

et al. 2010

memo

View full text Add to dashboard Cite

show abstract

Failure Analysis of Fire Tube Sleeve of Heater Treater

Srivastava

Katarki

2009

J Fail. Anal. and Preven.

View full text Add to dashboard Cite

The fire tube sleeve of a Heater Treater that was installed in an Oil and Gas processing unit ruptured after a service life of around 15 years. The detailed failure analysis was undertaken on this failed Incoloy 800 (UNS N08800) fire tube sleeve to ascertain the causes and mechanism of failure. The various studies indicated that the exposure of the sleeve to excessive temperature resulted in internal oxidation corrosion and caused of the failure. Additionally, Incoloy 800 is susceptible to sensitization in the temperature range of 540-1095°C which did occur and resulted in intercrystalline cracks causing grains to fall out of the metal leading to a thickness reduction. The main causes of failure were overheating and the resulting microstructural evolution and recommendations to prevent such failures in future are presented.

show abstract